Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood cancer
Biotech
Incyte scraps cancer-related anemia program after ph. 1/2 fail
Incyte is dropping a cancer-related anemia program after its investigational small molecule failed to improve symptoms in a phase 1/2 trial.
Darren Incorvaia
Dec 13, 2024 2:30pm
Lava burnt by failure clinical-stage cancer drug in phase 1
Dec 10, 2024 9:15am
AbbVie sues BeiGene over blood cancer drug trade secrets
Sep 11, 2024 10:17am
FDA rejects Regeneron bispecific, delaying rival to J&J, Pfizer
Aug 21, 2024 5:48am
FDA hands de novo clearance to Scopio's bone marrow pathology AI
Apr 17, 2024 12:56pm
AACR: Regeneron's multiple myeloma drug shows staying power
Apr 7, 2024 4:00pm
